Opinion: Chemoprevention: An essential approach to controlling cancer

Nature Reviews Cancer

Volumn 2, Issue 7, 2002, Pages 537-543

  Sporn, Michael B ^a   Suh, Nanjoo ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 5 AZA 2' DEOXYCYTIDINE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ARZOXIFENE; BETA CAROTENE; BEXAROTENE; CELECOXIB; CELL NUCLEUS RECEPTOR; CURCUMIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RALOXIFENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; REXINOID; RO 24 5531; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VORINOSTAT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; HODGKIN DISEASE; HUMAN; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TESTIS CANCER; ANIMAL; BIOLOGICAL MODEL; CHEMICAL MODEL; FEMALE; MALE; MORTALITY; NEOPLASM; TIME;

ANIMALS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0036637235     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc844     Document Type: Article

References (70)

1. Sporn, M. B.: Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res. 51, 6215-6218 (1991).
2. Sporn, M. B.: Chemoprevention Working Group. Prevention of cancer in the next millennium: report of theChemoprevention Working Group to the AmericanAssociation for Cancer Research.Cancer Res.59, 4743-4758 (1999).
3. O'Shaughnessy, J. A.:Treatment and prevention of intraepithelial neoplasia: an important target foraccelerated new agent development.Clin. Cancer Res. 8, 314-346 (2002).
4. Lippman, S. M. &Hong, W. K.: Cancer prevention by delay. Clin. Cancer Res.8, 305-313 (2002).
5. Lippman, S. M. &Hong, W. K.: The Oxford English Dictionary2nd edn Vol. 12. p. 444 (Clarendon Press, Oxford, 1989).
6. Pierce, G. B., Shikes, R. &Fink, L. M.:Cancer: A Problem of Developmental Biology(Prentice Hall, EnglewoodCliffs, New Jersey, 1978).
7. Mintz, B. &Fleischman, R. A.: Teratocarcinomas and other neoplasms as developmental defects in geneexpression.Adv. Cancer Res.34, 211-278 (1981).
8. Brivanlou, A. H. &Darnell, J. E. Jr.: Signal transductionand the control of gene expression.Science298, 813-818 (2002).
9. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P M. &Issa, J. P.: Alterations in DNA methylation: a fundamentalaspect of neoplasia.Adv. Cancer Res.72, 141-196(1998).
10. Robertson, K. D. &Jones, P. A.: DNA methylation: past, present and future directions.Carcinogenesis21, 461-467 (2000).
11. Marks, P. A.:Histone deacetylases and cancer: causes and therapies.Nature Rev. Cancer1, 194-202(2001).
12. Clark, W. H. Jr.: The nature of cancer: morphogenesis and progressive (self)-disorganization in neoplasticdevelopment and progression.Acta Oncologica34, 3-21 (1995).
13. Bissell, M. J. &Radisky, D.: Putting tumors in context.Nature Rev. Cancer1, 46-54 (2001).
14. Liotta, L. A. &Kohn, E. C.: The microenvironment of the tumor-host interface.Nature411, 375-379 (2001).
15. Hennekens, C. H.:Lack of effect of long-termsupplementation with p-carotene on the incidence ofmalignant neoplasms and cardiovascular disease.N. Engl. J. Med.334, 1145-1149 (1996).
16. Omenn, G. S.:Effects of a combination of p-carotene and vitamin A on lung cancer and cardiovascular disease.N. Engl. J. Med.334, 1150-1155 (1996).
17. Kelloff, G. J.: Perspectives on cancer chemoprevention research and drug development.Adv. Cancer Res.78, 199-334 (1999).
18. Mangelsdorf, D. J.:The nuclear receptor superfamily: the second decade.Cell83, 835-839 (1995).
19. Katzenellenbogen, B. S. &Katzenellenbogen, J. A.:Defining the 'S' in SERMs.Science295, 2380-2381(2002).
20. Fisher, B.:Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and BowelProject P-1 Study.J. Natl Cancer Inst.90, 1371-1388 (1998).
21. Jordan, V. C. &Morrow, M.: Tamoxifen, raloxifene, and the prevention of breast cancer.Endocr. Rev.20, 253-278 (1999).
22. Sporn, M. B., Suh, N. &Mangelsdorf, D. J.: Prospects for prevention and treatment of cancer with selective PPAR-ymodulators (SPARMs).Trends Mol. Med.7, 395-400(2001).
23. Cauley, J. A.:Continued breast cancer risk reduction in postmenopausal women treated with raloxifene. 4-yearresults from the MORE trial. Multiple outcomes ofraloxifene evalutaion.Breast Cancer Res. Treat.65, 125-134 (2001).
24. Suh, N.:Arzoxifene, a new selective estrogen receptor modulator for chemoprevention ofexperimental breast cancer.Cancer Res.61, 8412-8415 (2001).
25. Horvath, L. G.:Frequent loss of estrogen receptor-p expression in prostate cancer.Cancer Res.61, 5331-5335 (2001).
26. Lucia, M. S.:Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)-retinamide, and the vitamin Danalogue Ro24-5531 for androgen-promotedcarcinomas of the rat seminal vesicle and prostate.Cancer Res.55, 5621-5627 (1995).
27. Campbell-Thompson, M., Lynch, I. J. &Bhardwaj, B.: Expression of estrogen receptor (ER) subtypes and ERpisoforms in colon cancer.Cancer Res.61, 632-640 (2001).
28. Chawla, A., Repa, J. J., Evans, R. M. &Mangelsdorf, D. J.:Nuclear receptors and lipid physiology: opening theX-files.Science294, 1866-1870 (2001).
29. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A. &Lamph, W. W.: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causescomplete regression of mammary carcinoma.CancerRes.58, 479-484 (1998).
30. Wu, K.:Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.Cancer Epidemiol. Biomarkers Prev.11, 467-474 (2002).
31. Jones, G., Strugnell, S. A. &DeLuca, H. F.: Currentunderstanding of the molecular actions of vitamin D.Physiol. Rev.78, 1193-1231 (1998).
32. Guyton, K. Z., Kensler, T. W. &Posner, G. H.: Cancer chemoprevention using natural vitamin D and syntheticanalogs.Annu. Rev. Pharmacol. Toxicol.41, 421-442(2001).
33. Martinez, M. E. &Willett, N. S.: Calcium, vitamin D, and colorectal cancer: a review of the epidemiologicevidence.Cancer Epidemiol. Biomarkers Prev.7, 163-168 (1998).
34. Makishima, M.:Vitamin D receptor as a bile acid sensor that detoxifies the colon carcinogen lithocholicacid.Science296, 1313-1316 (2002).
35. Yanagisawa, J.:Convergence of transforming growth factor-p and vitamin D signaling pathways onSMAD transcriptional coactivators.Science283, 1317-1321 (1999).
36. Misteli, T.: Protein dynamics: implications for nuclear architecture and gene expression.Science291, 843-847(2001).
37. Reddy, B. S.:Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.Cancer Res.60, 293-297 (2000).
38. Steinbach, G.:The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatouspolyposis.N. Eng. J. Med.342, 1946-1952 (2000).
39. Gupta, R. A. &DuBois, R. N.: Colorectal cancerprevention and treatment by inhibition ofcyclooxygenase-2.Nature Rev. Cancer1, 11-21 (2001).
40. Bharti, A. C. &Aggarwal, B. B. Nuclear factor kB andcancer: its role in prevention and therapy.Biochem.Pharmacol(in the press).
41. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. &Baylin, S. B.: Synergy of demethylation andhistone deacetylase inhibition in the re-expression ofgenes silenced in cancer.Nature Genet.21, 103-107(1999).
42. Lantry, L. E.:5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumormodel.Carcinogenesis20, 343-346 (1999).
43. Ferrara, F. F.:Histone deacetylase-targeted treatment restores retinoic acid signaling anddifferentiation in acute myeloid leukemia.Cancer Res.61, 2-7 (2001).
44. Widschwendter, M.:Methylation and silencing of the retinoic acid receptor-p2 gene in breast cancer.J. NatlCancer Inst.92, 826-832 (2000).
45. Tang, B.:Transforming growth factor-p1 is a new form of tumor suppressor with true haploid insufficiency.Nature Med.4, 802-807 (1998).
46. Massague, J., Blain, S. W. &Lo, R. S:. TGF-p signaling in growth control, cancer, and heritable disorders.Cell103, 295-309 (2000).
47. De Caestecker, M. P., Piek, E. &Roberts, A. B.: Role of transforming growth factor-p signaling in cancer.J. NatlCancer Inst.92, 1388-1402 (2000).
48. Derynck, R., Akhurst, R. J. &Balmain, A.: TGF-p signaling in tumor suppression and cancer progression.NatureGenet.29, 117-129 (2001).
49. Kim, S. J., Im, Y. H., Markowitz, S. D. &Bang, Y. J.: Molecular mechanisms of inactivation of TGF-p receptorsduring carcinogenesis.Cytokine Growth Factor Rev.11, 159-168 (2000).
50. Chen, T.:Transforming growth factor-p receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res.61, 4679-4682 (2001).
51. Fiocchi, C.: TGF-p/Smad signaling defects in inflammatory bowel disease: mechanisms and possiblenovel therapies for chronic inflammation.J. Clin. Invest.108, 523-526 (2001).
52. Monteleone, G.:Blocking Smad restores TGF-p1 signaling in chronic inflammatory bowel disease.J. Clin.Invest.108, 601-609 (2001).
53. Danielsen, A. J. &Maihle, N. J.: The EGF/ErbB receptor family and apoptosis.Growth Factors20, 1-15 (2002).
54. Raben, D., Helfrich, B. A., Chan, D., Johnson, G. &Bunn, P. A. Jr.: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and incombination with radiation and chemotherapy as a newtherapeutic strategy in non-small cell lung cancer.Semin.Oncol.29, S37-S46 (2002).
55. Karin, M., Cao, Y, Greten, F. R. &Li, Z. W.: NF-kB in cancer: from innocent bystander to major culprit.NatureRev. Cancer2, 301-310 (2002).
56. Bromberg, J. &Darnell, J. E.: The role of STATs in transcriptional control and their impact on cellularfunction.Oncogene19, 2468-2473 (2000).
57. Turkson, J. &Jove, R.: STAT proteins: novel molecular targets for cancer drug discovery.Oncogene19, 6613-6626 (2000).
58. Malumbres, M. &Barbacid, M.: To cycle or not to cycle: a critical decision in cancer.Nature Rev. Cancer1, 222-231 (2001).
59. Teicher, B. A. (ed.)Tumor Models in Cancer Research.690 (Humana, Totowa, New Jersey, 2002).
60. Hong, W. K., Lippman, S. M., Hittleman, W. N. &Lotan, R.: Retinoid chemoprevention of aerodigestive cancer: frombasic research to the clinic.Clin. Cancer Res.1, 677-686(1995).
61. Sporn, M. B.: Hobson's choice and the need for combinations of new agents for the prevention andtreatment of breast cancer.J. Natl Cancer Inst.94, 242-243 (2002).
62. Song, C. Z., Tian, X. &Gelehrter, T. D.: Glucocorticoid receptor inhibits transforming growth factor-p signaling bydirectly targeting the transcriptional activation function ofSmad3.Proc. Natl Acad. Sci.96, 11776-11781 (1999).
63. Matsuda, T., Yamamoto, T., Muraguchi, A. &Saatcioglu, F.:Cross-talk between transforming growth factor-p andestrogen receptor signaling through Smad3.J. Biol.Chem.276, 42908-42914 (2001).
64. Chipuk, J. E.:The androgen receptor represses transforming growth factor-p signaling through interactionwith Smad3.J. Biol. Chem.277, 1240-1248 (2002).
65. Kang, H. Y.:From transforming growth factor-psignaling to androgen action: identification of Smad3as an androgen receptor coregulator in prostate cancercells.Proc. Natl Acad. Sci.98, 3018-3023 (2001).
66. Fu, M.:Peroxisome proliferator-activated receptor-y inhibits transforming growth factor-p-induced connectivetissue growth factor expression in human aortic smoothmuscle cells by interfering with Smad3.J. Biol. Chem.276, 45888-45894 (2001).
67. Ulloa, L., Doody, J. &Massague, J. Inhibition of transforming growth factor-beta/SMAD signalling by theinterferon-y/STAT pathway.Nature397, 710-713 (1999).
68. Bitzer, M.:A mechanism of suppression of TGF-p/SMAD signaling by NF-KB/RelA.Genes Dev.14, 187-197 (2000).
69. Bitzer, M.:American Cancer Society.Estimated Cancer Deaths and New Cases by Sex and Site: 1971 Cancer Facts andFigures(American Cancer Society, New York, 1970).
70. Jemal, A., Thomas, A., Murray, T. &Thun, M.: Cancer Statistics 2002. CA Cancer J. Clin.52, 23-47 2002.